Five things for pharma marketers to know: Friday, September 4

Longer-term use of AstraZeneca's Brilinta approved; Google streamlines health-related searches; Zarxio's price is higher than expected

Sandoz: Zarxio marketing to be similar to a branded-drug launch

Sandoz plans to take a branded approach as it launches the first FDA-approved biosimilar product.

Social Engagement: Leveling the Field

Social media has the potential to elevate challenger brands to the highest step on the podium. But with many companies still languishing in the blocks, ...

Latest

The MM&M Weekly News Quiz: September 4

The MM&M Weekly News Quiz: September 4

Test your knowledge in this week's edition of the MM&M Weekly News Quiz

New data expected at lung-cancer conference on experimental drug combos

New data expected at lung-cancer conference on experimental drug combos

The conference will offer a glimpse at new data testing possible treatment strategies for combination therapies in the first-line setting.

Five things for pharma marketers to know: Thursday, September 3, 2015

Five things for pharma marketers to know: Thursday, September 3, 2015

Novartis launches Zarxio, the first US biosimilar; UCB sells its generic business; one-third of children with ADHD are diagnosed before they turn six

ZS opens office in Singapore

ZS opens office in Singapore

Advertising and marketing agencies turn their attention to the pharma market in the Asia-Pacific region.

Judge's ruling allows Sandoz to begin marketing its biosimilar Zarxio

Judge's ruling allows Sandoz to begin marketing its biosimilar Zarxio

The motion denied Amgen's bid for a temporary injunction that would have prevented the launch of Zarxio, the first FDA-approved biosimilar and a competitor to Amgen's Neupogen.

Five things for pharma marketers to know: Wednesday, September 2

Five things for pharma marketers to know: Wednesday, September 2

Novartis and Amgen form neuroscience collaboration; the FDA approves a drug for people undergoing chemotherapy; a judge considers denying Pfizer's request to toss federal lawsuit

Domanico, founding creative behind Draftfcb Healthcare, passes away at 74

Domanico, founding creative behind Draftfcb Healthcare, passes away at 74

The longtime creative director was instrumental in building the powerhouse agency that is now called FCB Health.

Google and Sanofi partner in diabetes

Google and Sanofi partner in diabetes

The search giant and the drugmaker will develop new tools to monitor the disease and improve patient outcomes.

Five things for pharma marketers to know: Tuesday, September 1

Five things for pharma marketers to know: Tuesday, September 1

Amgen gives hefty discount to Repatha in Europe; Valeant partners with AstraZeneca on controversial psoriasis drug; Pfizer now offers single packages of Viagra

Is It Finally Time for Pharma to Change the Way It Uses Facebook?

Is It Finally Time for Pharma to Change the Way It Uses Facebook?

Pharma has hidden behind the ability to turn commenting off on Facebook pages, allowing marketers to use the channel much as they would a typical web page.

Pharma sales forces should act more like 'outcomes advocates'

Pharma sales forces should act more like 'outcomes advocates'

Sales reps that focus on creating value for HCPs could find new opportunities and improved access to those physicians, according to Accenture.

Five things for pharma marketers to know: Monday, August 31

Five things for pharma marketers to know: Monday, August 31

Kim Kardashian posts corrective information on Instagram and Twitter; DPP-4 inhibitors are linked to joint pain; doctors question off-label prescriptions of PCSK9 inhibitors

Five things for pharma marketers to know: Friday, August 28

Five things for pharma marketers to know: Friday, August 28

Amgen's Repatha receives FDA nod; Mylan shareholders vote in favor of Perrigo deal; doctors push for below-average price of experimental cancer drug

Agency Spotlight



Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.